| Trial ID: | L0816 |
| Source ID: | NCT03795558
|
| Associated Drug: |
Etelcalcetide
|
| Title: |
A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Etelcalcetide
|
| Outcome Measures: |
Primary: T50-Laboratory Test for measuring calcification, The changes in T50 values between the different study phases will be evaluated as the primary outcome., 32 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Prim. Priv. Doz. Dr. Daniel Cejka | Collaborators: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
37
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2019-05-01
|
| Completion Date: |
2022-03-01
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-23
|
| Locations: |
Ordensklinikum Linz GmbH Elisabethinen, Linz, Upper Austria, 4020, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT03795558
|
